Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Naveglitazar. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 19/20 | 1.00 |
| ▸ | PPARA known ✓ | Q07869 | 19/20 | 1.00 |
| ▸ | PPARD | Q03181 | 10/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naveglitazar SCHEMBL5374978 | 1.00 | PPARG (1.00) | PPARGPPARAPPARD | |
| Naveglitazar SCHEMBL2827844 | 1.00 | PPARG (1.00) | PPARGPPARAPPARD | |
| Naveglitazar SCHEMBL5383187 | 0.99 | PPARG (0.97) | PPARGPPARAPPARD | |
| SCHEMBL5380701 | 0.97 | PPARG (0.95) | PPARGPPARAPPARD | |
| SCHEMBL5375478 | 0.96 | PPARG (0.93) | PPARGPPARAPPARD | |
| SCHEMBL5382474 | 0.96 | PPARG (0.92) | PPARGPPARAPPARD | |
| SCHEMBL5382488 | 0.96 | PPARG (0.92) | PPARGPPARAPPARD | |
| SCHEMBL5375774 | 0.96 | PPARG (0.92) | PPARGPPARAPPARD | |
| SCHEMBL5394822 | 0.92 | PPARG (0.84) | PPARGPPARAPPARD | |
| SCHEMBL5383883 | 0.92 | PPARA (0.84) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200121665-A1 | PPAR GAMMA MODULATORS FOR TREATING CYSTIC DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2020-04-23 | — | — | US | claimed |
| US-20160128994-A1 | PPAR GAMMA MODULATORS FOR TREATING CYSTIC DISEASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2016-05-12 | — | — | US | claimed |
| EP-3003303-A1 | PPAR GAMMA MODULATORS FOR TREATING CYSTIC DISEASES | Indiana University Research And Technology Corporation (US) | 2016-04-13 | — | — | EP | claimed |
| WO-2014197820-A1 | PPAR GAMMA MODULATORS FOR TREATING CYSTIC DISEASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2014-12-11 | — | — | WO | claimed |
| WO-2012158123-A1 | COMPOUNDS AND METHODS FOR TREATING INSULIN RESISTANCE SYNDROME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-11-22 | — | — | WO | claimed |
| US-7192982-B2 | Modulators of peroxisome proliferator activated receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2007-03-20 | — | — | US | claimed |
| US-20050020684-A1 | Modulators of peroxisome proliferator activated receptors | ELI LILLY AND COMPANY | 2005-01-27 | — | — | US | claimed |
| EP-1392637-A2 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-03-03 | — | — | EP | claimed |
| WO-2002100813-A2 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | ELI LILLY AND COMPANY (US) | 2002-12-19 | — | — | WO | claimed |
| US-20210059997-A1 | PROPHYLACTIC AGENT AND/OR THERAPEUTIC AGENT FOR CATARACT, MEDICINAL COMPOSITION FOR PREVENTING AND/OR TREATING CATARACT, USE OF PPAR ACTIVATOR FOR PRODUCING SAME, AND EYEDROPS | UNIVERSITY OF FUKUI (JP) | 2021-03-04 | — | — | US | disclosed |
| EP-3733203-A1 | PROPHYLACTIC AGENT AND/OR THERAPEUTIC AGENT FOR CATARACT, MEDICINAL COMPOSITION FOR PREVENTING AND/OR TREATING CATARACT, USE OF PPAR ACTIVATOR FOR PRODUCING SAME, AND EYEDROPS | University of Fukui (JP) | 2020-11-04 | — | — | EP | disclosed |
| EP-3065723-B1 | COMPOUNDS FOR THE TREATMENT OF DIABETES AND DISEASE COMPLICATIONS ARISING FROM SAME | BEN GURION UNIV OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IL) | 2020-09-23 | — | — | EP | disclosed |
| CN-111511402-A | Agent for preventing and/or treating cataract, pharmaceutical composition for preventing and/or treating cataract, use of PPAR activator for producing the same, and eye drop | 国立大学法人福井大学 | 2020-08-07 | — | — | CN | disclosed |
| US-20200121665-A1 | PPAR GAMMA MODULATORS FOR TREATING CYSTIC DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2020-04-23 | — | — | US | disclosed |
| EP-1792620-A1 | MEDICINAL COMPOSITION CONTAINING DIABETES REMEDY | Sankyo Company, Limited (JP) | 2007-06-06 | — | — | EP | disclosed |
| US-20070049515-A1 | Therapeutic agent for diabetes containing insulin resistance improving agent | SANKYO COMPANY, LIMITED (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20070049515-A1 | Therapeutic agent for diabetes containing insulin resistance improving agent | SANKYO COMPANY, LIMITED (JP) | 2007-03-01 | — | — | US | disclosed |
| WO-2006094933-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | NYCOMED GMBH (DE) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006094942-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | NYCOMED GMBH (DE) | 2006-09-14 | — | — | WO | disclosed |
| JP-2006104199-A | AGENT FOR TREATMENT OF KERATOCONJUNCTIVE DISORDER | SANTEN PHARMACEUT CO LTD | 2006-04-20 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049515-A1 | Therapeutic agent for diabetes containing insulin resistance improving agent | GPR119, IAPP, INSR | PPARG 82/4885PPARA 69/4885PPARD 334/4885 |
| US-20050020684-A1 | Modulators of peroxisome proliferator activated receptors | NCOA4, PPARG, PPARA | PPARG 2/4885PPARA 3/4885PPARD 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.